

## Report from the Medical Oncology and Radiotherapy Subcommittee

SSG Working Group Meeting December 3<sup>rd</sup> and 4<sup>th</sup> 2018

### *Radiotherapy in inoperable osteosarcoma*

Jacob Engellau presented data from published studies showing that local recurrence-free survival rates >50% can be achieved with proton/carbon radiotherapy in localized, inoperable osteosarcoma. He will reach out to international centers hoping to establish a more formal collaboration.

### *Rhabdomyosarcoma: should we use pediatric chemotherapy protocols for adult patients? Presentation of recent results from pediatric studies and discussion*

Heidi Glosli presented recent data from the EpSSG RMS 2005 protocol, and Gustaf Østerlundh presented the CWS perspective on RMS. There are no data from similar randomized and/or prospective clinical studies in the adult population for RMS. It was decided that the SSG recommends using pediatric protocols for the treatment of adult patients with RMS, except the pleomorphic subtype, which should be treated similar to other non-rhabdo STSs. Dose adjustments and other modifications might be necessary due to toxicity. A new RMS-protocol (FaR-RMS) with no upper age limit is currently being finalized, and centers are encouraged to participate.

### *What's new? Novel therapies in sarcoma.*

- Olaratumab: Sharminah Mansoori presented a patient story and the experience with olaratumab was discussed.
- Larotrectinib: The recent FDA approval and the updated data presented at CTOS and ESMO were discussed.
- Atezolizumab in ASPS: Promising data were presented at CTOS, and these were discussed.

### *Study updates*

- *rEECur*: Kirsten Sundby Hall presented an update. The accrual is slower than expected, and central funding will end during 2019. Participating countries must apply for separate funding to continue the study.
- Morten Nielsen and Niels Junker presented a new phase 2 study in Copenhagen with injection of LTX-315 and adoptive T-cell therapy in STS. Referrals are welcome as soon as the legal and financial issues are sorted out.
- Akmal Safwat reminded on the project in Aarhus on serum biomarkers in bone and soft tissue sarcoma. Oslo is currently collecting data, and other SSG centers are encouraged to participate.
- Short updates on DOREMY (myxoid liposarcoma) and two phase 2 studies with pembrolizumab in Oslo were presented.

### *Administrative matters*

- Nina Jebsen and Jacob Engellau were unanimously re-elected as chairmen for the Radiotherapy Subcommittee.
- We continued the discussions from the plenary session on the future of SSG, with a focus on the future for clinical trials within the SSG. It is an option that one of the university hospitals is the study sponsor, and that the studies still are SSG studies, like the STOP-GIST

study. Akmal Safwat pointed out that also collaborative translational projects should be encouraged.

- The group thinks the e-mail discussion forum works well.

December 19<sup>th</sup> 2018

Jacob Engellau, Nina Jebsen and Kjetil Boye